Core Viewpoint - Teladoc Health has experienced a widening loss in Q3 2025, driven by a decline in its BetterHelp unit and overall revenue challenges, leading to a 14.8% drop in share price over the past month, underperforming the S&P 500 [1][2][3]. Financial Performance - The adjusted loss per share for Q3 2025 was 21 cents, which was narrower than the consensus estimate of 26 cents but wider than the previous year's loss of 19 cents [3]. - Operating revenues decreased by 2% year over year to $626.4 million, slightly beating the consensus estimate by 0.2% [3]. - Access fee revenues fell by 6% year over year to $520.9 million, missing the consensus estimate of $534 million [5]. - International revenues increased by 12% year over year to $116.7 million, surpassing the consensus mark of $105 million [6]. - Total costs and expenses decreased by 1% year over year to $678.4 million, lower than the estimate of $691.4 million [7]. Segment Performance - The Integrated Care segment's revenues grew by 2% year over year to $389.5 million, beating the consensus estimate [8]. - The BetterHelp segment saw revenues decline by 8% year over year to $236.9 million, missing the consensus estimate [9]. Operational Metrics - Total visits to Teladoc Health were 4.1 million in Q3, a 1% increase year over year, exceeding the consensus estimate of 4 million [10]. - U.S. Integrated Care members reached 102.5 million as of September 30, 2025, a 9% increase year over year, surpassing the consensus mark [11]. Financial Position - Cash and cash equivalents stood at $726.2 million, down 44.1% from the end of 2024 [12]. - Total assets decreased by 18.1% to $2.9 billion, while total stockholders' equity fell by 6.6% [12]. Future Outlook - For Q4 2025, total revenues are expected to be between $622 million and $652 million, with an adjusted EBITDA forecasted between $73 million and $90 million [15]. - The 2025 revenue outlook has been adjusted to between $2.510 billion and $2.539 billion, with a projected net loss per share between $1.25 and $1.10 [18]. - The Integrated Care segment is expected to see growth of 2.4-3.5% year over year, while the BetterHelp segment anticipates a decline of 9.2-8% [16][17]. Industry Comparison - Teladoc operates within the Zacks Medical Services industry, where Elevance Health reported revenues of $50.09 billion, reflecting a year-over-year increase of 12% [23].

Industry Overview - Telemedicine is transforming healthcare access, driven by regulatory measures like the 1135 waiver and the Coronavirus Preparedness Act, which expanded Medicare coverage for telehealth visits [1] - The demand for remote medical services is accelerating the adoption of telehealth solutions, benefiting industry players [1] Company Analysis: Teladoc Health (TDOC) - Teladoc is strengthening its leadership in integrated care in the U.S. by broadening its service offerings and improving patient outcomes [3] - The Prism care delivery platform is a major strategic priority, with pilot programs expected to launch in 2026, indicating future growth potential [3] - An acquisition-led strategy has expanded Teladoc's distribution capabilities and clinical offerings, targeting scalable, high-growth solutions [4] - International operations are increasingly important as competition in the U.S. market intensifies, with plans to expand across Europe, South America, and Asia [5] - Teladoc utilizes advanced technologies like AI and machine learning to enhance care delivery across various medical specialties [6] - The company has a solid liquidity position with $726 million in cash and cash equivalents and free cash flow of $113 million, but continues to operate at a loss [7] - TDOC shares have declined by 22.5% year to date, underperforming the industry's growth of 4.3% [7] Company Analysis: LifeMD (LFMD) - LifeMD is emerging as a leading provider of virtual primary care, with a diversified portfolio and growth momentum in key areas [8] - The company aims to scale its virtual women's and behavioral health businesses and enhance its weight management offerings in 2026 [9] - LifeMD's weight-management platform is expected to benefit from collaborations with pharmaceutical partners, broadening its addressable market [11] - The RexMD men's health brand will expand through personalized medications and hormone therapies to improve patient outcomes [12] - LifeMD has secured regulatory approval for its compounding pharmacy, enabling scalable production of personalized medications [13] - LFMD shares have lost 19.4% year to date, also underperforming the industry [13] Financial Estimates - The Zacks Consensus Estimate for TDOC's bottom line implies year-over-year improvements of 80.4% and 26.6% for 2025 and 2026, respectively [14] - The Zacks Consensus Estimate for LFMD's bottom line implies year-over-year improvements of 71.7% and 346.7% for 2025 and 2026, respectively [15] Valuation Metrics - TDOC shares are trading at a forward 12-month price-to-sales multiple of 0.49, below its five-year median of 1.49 [16] - LFMD's forward 12-month price-to-sales multiple is 0.65, also below its five-year median of 1.02 [16] Conclusion - Teladoc is a leading player in the telehealth market with consistent revenue growth but faces challenges in achieving profitability [17] - LifeMD presents a compelling growth opportunity in virtual care, with improving profitability and strong long-term growth catalysts [17] - Both companies carry a Zacks Rank 3 (Hold), but LFMD is considered to have an edge over TDOC [18]

Group 1: Industry Overview - Telehealth has become an integrated and essential part of the healthcare landscape, transforming delivery, access, and convenience [1] - The global telemedicine market size is projected to grow from USD 160.13 billion in 2025 to approximately USD 709.69 billion by 2034, with a CAGR of 17.99% from 2025 to 2034 [2] Group 2: Company Insights - Teladoc Health (NASDAQ: TDOC) is recognized as the largest telehealth company by revenue and global reach, with a new integration with TytoCare to enhance virtual primary and urgent care [3] - The consensus estimate for TDOC's 2025 revenues indicates a year-over-year decline, while the estimate for 2026 suggests a year-over-year increase [4] - On November 14, 2025, a Director at Teladoc Health purchased 10,000 shares of the company's stock, indicating insider confidence [4] Group 3: Stock Performance - After reaching a new 60+ day low on November 17, the stock closed strong, showing signs of a price reversal [5] - The Real Motion momentum indicator shows potential for the stock, with the 50-day moving average above the 200-day moving average [6] - The stock needs to hold recent lows and continue moving towards the 50 and 200-day moving averages, with a target around 8.15 [6]

Core Insights - Teladoc Health, Inc. (TDOC) is enhancing its virtual care offerings by integrating TytoCare's FDA-approved Home Smart Clinic into its Primary360 and 24/7 Care programs, starting in 2026, allowing members to access clinical-grade remote exams [1][9] - TytoCare's technology enables comprehensive remote assessments of various health metrics, including lung and heart sounds, with its AI-powered Lung Sounds Suite recognized as a significant innovation [2][9] - This integration aims to strengthen TDOC's competitive position in the telehealth market, potentially leading to quicker interventions and improved chronic care management for conditions like asthma and hypertension [3][4] Company Developments - The integration of TytoCare's diagnostic tools is a response to the increasing demand for at-home healthcare solutions, indicating a shift towards more accessible diagnostics [4][9] - TDOC's cautious rollout strategy, starting with a select group of customers, suggests a focus on testing adoption and reimbursement alignment to ensure successful implementation [5] Market Performance - Year-to-date, TDOC shares have declined by 23%, contrasting with the industry's growth of 4.9%, highlighting the challenges faced by the company in the current market environment [8]

Group 1 - The article discusses the potential for investors to identify undervalued stocks that are mispriced by the market in Q4 [1] - Stone Fox Capital is an RIA based in Oklahoma, led by Mark Holder, who has extensive experience in investing and portfolio management [2] - The investing group "Out Fox The Street" provides stock picks, model portfolios, daily updates, and real-time alerts to help investors uncover potential multibaggers while managing portfolio risk [2]

Group 1 - The article discusses the potential for investors to identify undervalued stocks that are mispriced by the market in Q4 [1] - Stone Fox Capital is an RIA based in Oklahoma, led by Mark Holder, who has extensive experience in investing and portfolio management [2] - The investing group "Out Fox The Street" provides stock picks, deep research, model portfolios, daily updates, and real-time alerts to help investors uncover potential multibaggers while managing portfolio risk [2]

Core Insights - Teladoc Health (TDOC) is positioned to benefit from the growing telemedicine market, driven by regulatory support and increasing demand for remote healthcare services [2][10] - The U.S. telehealth market is projected to grow from $42.61 billion in 2024 to $358.96 billion by 2034, providing significant opportunities for Teladoc [4] - Teladoc's partnership with Microsoft aims to enhance its Solo platform with AI, improving clinical documentation and care quality [3][10] Company Positioning - Teladoc continues to invest heavily in client acquisition, provider network development, and technology innovation, which strengthens its competitive position in virtual care [5] - The company aims to be the primary "front door" to the healthcare system for millions of members globally [5] Market Dynamics - HCA Healthcare and CVS Health are also well-positioned to capitalize on telemedicine growth, with HCA integrating virtual care across its network and CVS leveraging its retail and pharmacy services [6][7] - Both competitors are investing in digital health infrastructure and remote monitoring to seize opportunities in the evolving healthcare landscape [8] Financial Performance - Teladoc's shares have decreased by 17.2% year to date, contrasting with a 3.1% increase in the industry [9] - The company is trading at a forward 12-month price-to-sales multiple of 0.53, higher than the industry average of 0.45 [11] Estimates and Projections - The Zacks Consensus Estimate for TDOC's fourth-quarter 2025 loss has narrowed by 1 cent, while the first-quarter 2026 loss has improved by 2 cents over the past 30 days [12] - The consensus estimates for 2025 revenues indicate a year-over-year decline, while those for 2026 suggest a year-over-year increase [12]

Core Insights - Teladoc Health (TDOC) reported third-quarter 2025 results with revenues of $626.4 million, a 2.2% decline year over year, but exceeded the Zacks Consensus Estimate. The company experienced a wider loss compared to the previous year [1][3][9]. Financial Performance - Revenues of $626.4 million decreased by 2.2% year over year, with the Integrated Care segment revenues of $389.5 million increasing by 2%, while BetterHelp segment revenues fell by 8% to $236.9 million [3][4][9]. - Adjusted EBITDA was $70 million, down 16% year over year, but at the high end of guidance, resulting in an adjusted EBITDA margin of 11.2% [3][5]. - The net loss per share was 21 cents, wider than the 19 cents loss in the same quarter last year, but beat the consensus estimate by 19.2% [5][9]. Market Position and Strategy - Teladoc is a leading player in the telehealth market, targeting a $261 billion total addressable market in the U.S. [2]. - The company is enhancing its leadership in integrated care by expanding service offerings and improving patient outcomes through initiatives like the Prism care delivery platform, with active pilots expected to launch in 2026 [6]. - An acquisition-driven growth strategy has broadened Teladoc's distribution capabilities and enriched its service portfolio [7]. Geographic Performance - U.S. revenues decreased by 5% to $509.8 million, while international revenues increased by 12% to $116.7 million, providing crucial diversification amid intensifying competition in the U.S. market [4][8]. Future Outlook - Teladoc expects consolidated revenues for 2025 to be between $2.510 billion and $2.539 billion, with adjusted EBITDA projected between $270 million and $287 million [5][9]. - Free cash flow is anticipated to be in the range of $170 million to $185 million [5]. Valuation and Market Comparison - Teladoc's stock has lost 12.2% year to date, contrasting with industry peers like HCA Healthcare and CVS Health, which have gained 57.1% and 73.9%, respectively [12][13]. - The company is currently trading at a forward price-to-sales multiple of 0.56, higher than the industry average of 0.46, indicating a premium valuation [17][18]. Industry Trends - The telehealth market is experiencing rising demand for remote medical expertise, positioning Teladoc to benefit from this trend as telemedicine enhances healthcare access [19].

Core Viewpoint - Teladoc Health is facing ongoing challenges despite a recent uptick in stock performance, with a significant decline in revenue and increased competition in the telehealth sector [2][3][10] Financial Performance - Year-to-date, Teladoc's shares have decreased by 8%, although they have gained 21% over the past six months [2] - Third-quarter revenue fell by 2% year-over-year to $626.4 million, and the loss per share increased to $0.28 from $0.19 in the previous year [3] Leadership Changes - Recent leadership changes, including the replacement of the CFO and the upcoming CEO transition, may have contributed to a more optimistic outlook among some investors [4] Valuation Metrics - The company's forward price-to-sales (P/S) ratio is currently at 0.6, suggesting it may be trading at a deep discount [4] Growth Opportunities - Teladoc aims to expand insurance coverage for its BetterHelp virtual therapy service, which could enhance performance in that segment [5][6] - The acquisition of UpLift, a virtual mental health service, could potentially increase sales if marketing efforts successfully boost adoption [6] - International revenue growth presents another opportunity for improvement, although challenges remain [7] Competitive Landscape - The virtual care segment is highly competitive, with Teladoc's user base for BetterHelp declining despite aggressive marketing [8] - Competitors already have established relationships with insurers, making it uncertain whether Teladoc can attract enough new members [9] Investment Outlook - Given the company's struggles to achieve profitability in the U.S. market, there are doubts about its ability to perform better internationally [10]

Membership and Enrollment - U.S. Integrated Care members increased by 8.6 million, or 9%, to 102.5 million at September 30, 2025, compared to the same period in 2024[123] - Chronic care program enrollment decreased by 1% to 1.165 million at September 30, 2025, compared to 1.179 million at September 30, 2024[124] - BetterHelp paying users decreased by 4% to 0.382 million for the three months ended September 30, 2025, compared to 0.398 million for the same period in 2024[126] Revenue Performance - Total revenue for Q3 2025 was $626.4 million, a decrease of $14.1 million, or 2%, compared to Q3 2024[141] - Revenue from the BetterHelp segment decreased, while Integrated Care segment revenue increased, contributing to the overall revenue change[142] - Total revenue for the nine months ended September 30, 2025, was $1,887.7 million, a decrease of $41.4 million, or 2%, compared to the same period in 2024[142] - U.S. revenue for Q3 2025 was $509.8 million, a decrease of $26.4 million, or 5%, compared to Q3 2024[141] - International revenue for Q3 2025 was $116.7 million, an increase of $12.3 million, or 12%, compared to Q3 2024[141] - BetterHelp total revenue decreased by $19.9 million, or 8%, to $236.9 million for the three months ended September 30, 2025, and decreased by $73.7 million, or 9%, to $717.2 million for the nine months ended September 30, 2025[167] Expenses and Costs - Cost of revenue for Q3 2025 was $187.2 million, an increase of $7.4 million, or 4%, compared to Q3 2024[143] - Advertising and marketing expenses for Q3 2025 were $168.0 million, a decrease of $9.5 million, or 5%, compared to Q3 2024[144] - Technology and development expenses for Q3 2025 were $67.6 million, a decrease of $4.8 million, or 7%, compared to Q3 2024[146] - General and administrative expenses decreased by $11.7 million, or 10%, to $102.6 million for the three months ended September 30, 2025, compared to $114.2 million for the same period in 2024[148] - Research and development costs for the three months ended September 30, 2025, were $21.5 million, a decrease from $22.4 million in the same period of 2024[147] - Integrated Care cost of revenue increased by $11.2 million, or 10%, to $124.3 million for the three months ended September 30, 2025[163] - Cost of revenue decreased by $3.2 million, or 5%, to $62.4 million for the three months ended September 30, 2025, primarily due to lower therapist costs[168] - Advertising and marketing expenses decreased by $8.8 million, or 6%, to $134.6 million for the three months ended September 30, 2025, reflecting lower spending on digital and media advertising[169] - Other segment expenses increased by $3.5 million, or 11%, to $36.0 million for the three months ended September 30, 2025, driven by higher employee compensation[170] Profitability and Loss - Net loss for Q3 2025 was $49.5 million, an increase of $16.2 million, or 49%, compared to Q3 2024[140] - Adjusted EBITDA for Q3 2025 was $69.9 million, a decrease of $13.3 million, or 16%, compared to Q3 2024[140] - Adjusted EBITDA for the three months ended September 30, 2025, was $3.8 million, a decrease of $11.4 million or 75% compared to the prior year[167] Cash Flow and Financial Position - Net cash provided by operating activities was $206.6 million for the nine months ended September 30, 2025, compared to $207.8 million for the same period in 2024[176] - Cash used in investing activities was $231.7 million for the nine months ended September 30, 2025, significantly higher than $94.4 million for the same period in 2024[178] - Free cash flow was $113.5 million for the nine months ended September 30, 2025, compared to $113.4 million for the same period in 2024[181] - As of September 30, 2025, the company had cash and cash equivalents totaling $726.2 million, sufficient to meet working capital and capital expenditure needs for at least the next 12 months[172] Strategic Outlook and Risks - The company expects tariffs on imported goods to impact consolidated results of operations, particularly for components used in virtual healthcare devices[121] - The company faces risks from competition as health plans may develop solutions that replicate its services[123] - The company aims to increase membership to drive innovation and enhance member experiences[123] - The company’s business is subject to seasonality, with higher visit and fee revenue typically occurring in the first and fourth quarters[127] Impairments and Costs - Goodwill impairments recognized for the three months ended September 30, 2025, totaled $12.6 million, contributing to a year-to-date total of $71.8 million[149] - Acquisition, integration, and transformation costs were $1.9 million for the three months ended September 30, 2025, compared to $0.5 million for the same period in 2024[150] - Restructuring costs for the three months ended September 30, 2025, were $2.0 million, down from $3.6 million in the same period of 2024[151][152]